New schizophrenia drug enters first human tests
NCT ID NCT06504290
Summary
This is an early-stage study to check the safety and how the body processes a new potential schizophrenia medication called VV119. It will first test the drug in healthy adults, then in a small group of patients with schizophrenia to see if it is safe and how it affects their symptoms. The main goal is to find a safe dose and understand how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Beijing Anding Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact
-
Beijing Huilongguan Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Xi'an Mental Health Center
RECRUITINGXi’an, Shanxi, China
Contact
Conditions
Explore the condition pages connected to this study.